The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Drug pricing realpolitik & a (premature) look at IPOs

By Damian Garde

The READOUT
The Readout

Dancing fentanyl tubes, & a holiday for generics

By Damian Garde

The READOUT
The Readout

The future of NASH & an IPO ‘chess game’

By Damian Garde

The READOUT
The Readout

Gilead’s NASH stumble & the problem with ‘anti-aging’ biotech

By Damian Garde

The READOUT
The Readout

Sean Parker tells all(ish) & pricing questions for Senate

By Damian Garde

The READOUT
The Readout

Sobering news for science & a father-son biotech saga

By Damian Garde

The READOUT
The Readout

Gene therapy stumbles in DMD & decoding ‘dormant’ cancer

By Damian Garde

The READOUT
The Readout

A bellwether biotech IPO & Regeneron’s cancer counternarrative

By Damian Garde

The READOUT
The Readout

Explaining biosimilars & the race to halt a rare disease

By Damian Garde

The READOUT
The Readout

The CF patient gap & a state of pharma speech

By Damian Garde

The READOUT
The Readout

The problem with viral biotech stories & why CRISPR is hard

By Damian Garde

The READOUT
The Readout

Why treating pain is hard & Biogen’s Alzheimer’s odds

By Damian Garde

The READOUT
The Readout

Biotech goes crypto & a startup redemption tour

By Damian Garde

The READOUT
The Readout

Insys on trial & preventing Theranos 2.0

By Damian Garde

The READOUT
The Readout

Opioid execs go to trial & Pfizer’s Chinese payment plan

By Damian Garde

The READOUT
The Readout

An SEC-free IPO & how the FDA might skirt the shutdown

By Damian Garde

The READOUT
The Readout

Biotech fundraising falters & Vertex fires its second in command

By Damian Garde

The READOUT
The Readout

Editas edits its org chart & sequencing goes to the dogs

By Damian Garde

The READOUT
The Readout

Capping NIH indirect costs & Celgene’s legacy of grit

By Damian Garde

The Readout

ICYMI: Everything you need to know about JPM19

By Damian Garde

The READOUT
The Readout

FDA furlough finances & Allergan’s other Restasis risk

By Damian Garde

The READOUT
The Readout

Digital chemo & dueling Theranos documentaries

By Damian Garde

The READOUT
The Readout

A 37-year biotech saga & the shutdown squeeze on IPOs

By Damian Garde

The READOUT
The Readout

The shutdown claims a biotech victim & the state of #SFrexit

By Damian Garde

The READOUT
The Readout

Trump’s pricing fiction & the pitfalls of hype

By Damian Garde

The READOUT
The Readout

The sound of #JPM19 & how not to be ‘dumb’ in biotech

By Damian Garde

The READOUT
The Readout

The end of #JPM19 & the state of Chinese biotech

By Damian Garde

The READOUT
The Readout

Amarin’s hints & the gift that is Keytruda

By Damian Garde

The Readout

Moderna makes its case, $1 million is cheap, & it’s an FDA waiting game

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy